Bone Mineral Density | malecare.org

Comparison Evaluating Bone Mineral Density Changes in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

The current standard hormone therapy (ADT) for men with advanced prostate cancer is a class of drugs called Luteinising hormone-releasing hormone agonists (LHRHa). These drugs reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss as a side effect of the ADT. Using transdermal (skin patches) oestradiol is a potential alternative to [...]

By Malecare|2016-04-05T12:04:43-04:00April 5th, 2016|Advanced Prostate Cancer, Bone Health, Bone Mineral Density, Bones and Prostate Cancer, Drugs & Treatments, estrogen patches, Hormone Therapy, Research, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales|0 Comments

Prevalence of Fractures Among Men with Stage IV Prostate Cancer

Many of us believe that the risk developing bone fractures is more common in men who have stage 4 prostate cancer that has developed distant metastasis than those men with stage 4 prostate cancer that do not have distant metastasis. This increased risk, or actually the increase of fractures has significant clinical consequences, such as [...]

By Malecare|2014-03-28T16:51:46-04:00March 28th, 2014|Advanced Prostate Cancer, Bone Mineral Density, Metastases, Uncategorized|0 Comments

Enzalutamide (Xtandi) Monotherapy Highly Active in Men Who Have Not Had Prior ADT

Enzalutamide (Xtandi) monotherapy induced striking declines in prostate-specific antigen (PSA) in a majority of patients with hormone-naive prostate cancer in a phase II trial, and this oral agent appears to have little effect on bone mineral density. If these findings are confirmed in a phase III trial, then enzalutamide may be an alternative to androgen [...]

By Malecare|2017-10-19T10:49:35-04:00August 7th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Enzalutamide (MDV-3100), Hormone Therapy, Uncategorized, Understanding APC, Xtandi|0 Comments

FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Men with Prostate Cancer Undergoing ADT

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in men receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. Men receiving ADT are at high risk for developing fractures, including vertebral fractures, which can cause paralysis. "Bone loss [...]

By Malecare|2011-09-19T10:59:59-04:00September 19th, 2011|Advanced Prostate Cancer, Bone Mineral Density, Drugs & Treatments, FDA, General Information, Hormone Therapy, Prolia (denosumab), Uncategorized, Understanding APC|3 Comments

What Causes Bone Fractures in Prostate Cancer?

We all know that one of the common problems many of us will confront when fighting prostate cancer is experiencing bone fractures. Somtimes these fractures happen for little or no obvious cause. Why are bone fractures, especially spontaneous fractures (without any evident reason) so common in prostate cancer? […]

By Malecare|2010-11-02T09:52:17-04:00November 2nd, 2010|Advanced Prostate Cancer, bisphosphonates, Bone Mineral Density, Diet and Supplements, Drugs & Treatments, Hormone Therapy, Uncategorized|1 Comment